GSA Capital Partners LLP Grows Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA

GSA Capital Partners LLP boosted its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 1,001.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 872,985 shares of the biotechnology company’s stock after acquiring an additional 793,763 shares during the period. GSA Capital Partners LLP’s holdings in Iovance Biotherapeutics were worth $2,383,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IOVA. Palo Alto Investors LP raised its stake in Iovance Biotherapeutics by 122.1% during the third quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after purchasing an additional 4,188,803 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Iovance Biotherapeutics by 202.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after purchasing an additional 3,869,617 shares in the last quarter. Vanguard Group Inc. raised its stake in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after purchasing an additional 3,148,096 shares in the last quarter. Bank of America Corp DE raised its stake in Iovance Biotherapeutics by 55.8% during the third quarter. Bank of America Corp DE now owns 6,279,230 shares of the biotechnology company’s stock valued at $13,626,000 after purchasing an additional 2,249,662 shares in the last quarter. Finally, Invenomic Capital Management LP raised its stake in shares of Iovance Biotherapeutics by 27.1% in the third quarter. Invenomic Capital Management LP now owns 10,541,608 shares of the biotechnology company’s stock valued at $22,875,000 after acquiring an additional 2,246,945 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IOVA shares. Barclays increased their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wall Street Zen raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Citizens Jmp raised shares of Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 target price on the stock in a research note on Tuesday, March 3rd. Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Iovance Biotherapeutics has an average rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $3.39 on Tuesday. The company has a market capitalization of $1.51 billion, a PE ratio of -3.57 and a beta of 0.69. Iovance Biotherapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $5.63. The firm’s 50-day moving average is $3.75 and its 200 day moving average is $3.00.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The company had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm’s revenue was up 44.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.36) EPS. Sell-side analysts forecast that Iovance Biotherapeutics, Inc. will post -0.6 EPS for the current fiscal year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.